Rationale and design of randomized evaluation of aggressive or moderate lipid lowering therapy with pitavastatin in coronary artery disease (REAL-CAD) trial

REAL-CAD Trial Investigaters

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Large-scale clinical trials in patients in Western countries with coronary artery disease (CAD) have found that aggressive lipid-lowering therapy using high-dose statins reduces cardiovascular (CV) events further than low-dose statins. However such evidence has not yet been fully established in Asian populations including in Japan. The Randomized Evaluation of Aggressive or Moderate Lipid-Lowering Therapy with Pitavastatin in Coronary Artery Disease (REAL-CAD) study addresses whether intensification of statin therapy improves clinical outcomes in Japanese patients with CAD. REAL-CAD is a prospective multicenter randomized open-label blinded-endpoint physician-initiated phase 4 trial in Japan. The study will recruit up to 12,600 patients with stable CAD. Patients are assigned to receive either pitavastatin 1 mg/day or pitavastatin 4 mg/day. LDL-C levels are expected to reach approximate mean values of 100 mg/dL in the low-dose pitavastatin group 80 mg/dL in the high-dose group. The primary endpoint is the time to occurrence of a major CV event including CV death non-fatal myocardial infarction non-fatal ischemic strokeunstable angina requiring emergency hospitalization during an average of 5 years. The large number of patients the long follow-up period in the REAL-CAD study should ensure that there is adequate power to definitively determine if reducing LDL-C levels to approximately 80 mg/dL by high-dose statin can provide additional clinical benefit. After the study is completed we will have categorical evidence on the optimal statin dose target LDL-C level for secondary prevention in Japanese patients.

Original languageEnglish
Pages (from-to)315-320
Number of pages6
JournalInternational heart journal
Volume59
Issue number2
DOIs
Publication statusPublished - 2018

Keywords

  • Cardiovascular events
  • High-dose statin therapy
  • LDL cholesterol
  • Long-term outcomes
  • Myocardial infarction
  • Secondary prevention
  • Stroke
  • Unstable angina

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Rationale and design of randomized evaluation of aggressive or moderate lipid lowering therapy with pitavastatin in coronary artery disease (REAL-CAD) trial'. Together they form a unique fingerprint.

  • Cite this